Peter M. Haverty

11.1k citations

38 papers · 3.3k indexed · h-index 29

Cancer Research top 2%
- Cancer Genomics and Diagnostics 8
Molecular Biology top 5%
- Gene expression and cancer classification 9
- Bioinformatics and Genomic Networks 7
- Genomics and Chromatin Dynamics 7
- Epigenetics and DNA Methylation 4
- Ubiquitin and proteasome pathways 4
- Molecular Biology Techniques and Applications 3
Oncology top 5%
- Cancer-related Molecular Pathways 4
Pathology and Forensic Medicine top 5%
Rheumatology top 5%

Co-authors: Zemin Zhang Richard Bourgon Lori S. Friedman John Chant Klaus P. Hoeflich Marcia Belvin Robert L. Yauch David Stokoe
Cited by: Cancer Research Molecular Biology Oncology
Journals: Clinical Cancer Research (4 papers)Cancer Research (4 papers)Nucleic Acids Research (4 papers)
Partner nations: United States France Singapore

In The Last Decade

Peter M. Haverty

37 papers receiving 3.2k citations

Peers

Countries citing papers authored by Peter M. Haverty

Since Specialization

Citations

This map shows the geographic impact of Peter M. Haverty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter M. Haverty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter M. Haverty more than expected).

Fields of papers citing papers by Peter M. Haverty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter M. Haverty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter M. Haverty. The network helps show where Peter M. Haverty may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Peter M. Haverty, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter M. Haverty Line = papers co-authored together Peter M. Haverty links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Super-enhancer acquisition drives oncogene expression in triple negative breast cancer PLoS ONE ·Ryan Raisner,Russell Bainer,Peter M. Haverty,Marie-Christine Le Guellec,Karen E. Gascoigne	2020	21
2	Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation Cell Reports ·Ryan Raisner,Samir Kharbanda,Lingyan Jin,Edwin E. Jeng,Emily Chan,Mark Merchant,Peter M. Haverty,Russell Bainer,Tommy K. Cheung,David Arnott,E. Megan Flynn,F. Anthony Romero,Steven Magnuson,Karen E. Gascoigne	2018	223
3	Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer Cancer Research ·Lingyan Jin,貫一水村,Emily Chan,田村直之,Ehud Segal,Mark Merchant,Samir Kharbanda,Ryan Raisner,Peter M. Haverty,Zora Modrušan,Justin Q. Ly,Edna F. Choo,Susan Kaufman,Maureen H. Beresini,F. Anthony Romero,Steven Magnuson,Karen E. Gascoigne	2017	105
4	Proline Starvation Induces Unresolved ER Stress and Hinders mTORC1-Dependent Tumorigenesis Cell Metabolism ·Nisebita Sahu,Philip Kantrowitz,Min Gao,Wendy Sandoval,Peter M. Haverty,Jinfeng Liu,Jean-Philippe Stéphan,Benjamin Haley,Marie Classon,Georgia Hatzivassiliou,Jeff Settleman	2016	83
5	Reproducible pharmacogenomic profiling of cancer cell line panels Nature ·Peter M. Haverty,Eva Lin,Jenille Tan,Yihong Yu,Anna P. Grøgaard,Steve Lianoglou,Richard M. Neve,Scott E. Martin,Jeff Settleman,Robert L. Yauch,Richard Bourgon	2016	185
6	An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies Clinical Cancer Research ·Jyoti Asundi,Lisa Crocker,Jarrod R. Tremayne,Peter S. Chang,Chie Sakanaka,Bakrudeen Hyder Ali Nizam,Susan D. Spencer,Sreedevi Chalasani,Elizabeth Luis,Karen E. Gascoigne,Rupal Desai,Rajiv Raja,Brad A. Friedman,Peter M. Haverty,Paul Polakis,Ron Firestein	2015	28
7	Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma Cancer Cell ·Hayley J. Sharpe,Grégoire Pau,Gerrit J.P. Dijkgraaf,Nicole Basset‐Séguin,Zora Modrušan,Thomas Januario,Vickie Tsui,Alison B. Durham,Andrzej A. Dlugosz,Peter M. Haverty,Richard Bourgon,Jean Y. Tang,Kavita Y. Sarin,Luc Dirix,David C. Fisher,Charles M. Rudin,Howard Sofen,Michael R. Migden,Robert L. Yauch,Frédéric J. de Sauvage	2015	296
8	Human Biosample Authentication Using the High-Throughput, Cost-Effective SNPtraceTM System PLoS ONE ·L. P. Garrod,Mamie Yu,Peter M. Haverty,Julie Koeman,Janet Ziegle,N. Piejos,Richard Bourgon,Richard M. Neve	2015	30
9	Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes Cancer Research ·Genee Y. Lee,Peter M. Haverty,Li Li,Noelyn M. Kljavin,Richard Bourgon,James Lee,Howard M. Stern,Zora Modrušan,Somasekar Seshagiri,Zemin Zhang,A Atabo,David Stokoe,Jeffrey Settleman,Frédéric J. de Sauvage,Richard M. Neve	2014	125
10	Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics Arthritis Research & Therapy ·Glynn Dennis,Cécile Holweg,Sarah Kummerfeld,David F. Choy,Audi Setiadi,Jason A. Hackney,Peter M. Haverty,Houston Gilbert,Wei Lin,Lauri Diehl,Sven Fischer,Çiğdem Güngör,David Musselman,Micki Klearman,Cem Gabay,Arthur Kavanaugh,Judith Endres,David A. Fox,Flavius Martin,Michael J. Townsend	2014	265
11	Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors Clinical Cancer Research ·David S. Shames,Kristi Elkins,Kimberly Walter,Thomas Holcomb,Pan Du,Dane Mohl,Yang Xiao,황홍구,Peter M. Haverty,Bianca M. Liederer,Xiaorong Liang,Robert L. Yauch,Thomas O’Brien,Richard Bourgon,Hartmut Koeppen,Lisa D. Belmont	2013	59
12	Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models Clinical Cancer Research ·Jill M. Spoerke,Carol O’Brien,Ling Huw,Hartmut Koeppen,Jane Fridlyand,Rainer K. Brachmann,Peter M. Haverty,Ajay Pandita,Sankar Mohan,Deepak Sampath,Lori S. Friedman,Leanne Ross,Garret M. Hampton,Lukas C. Amler,David S. Shames,Mark R. Lackner	2012	149
13	ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors Molecular Cancer Therapeutics ·Georgia Hatzivassiliou,Bonnie Liu,Carol O’Brien,Jill M. Spoerke,Klaus P. Hoeflich,Peter M. Haverty,Robert Soriano,William F. Forrest,Sherry Heldens,Huifen Chen,Karen Toy,Connie Ha,Wei Zhou,Kyung Song,Lori S. Friedman,Lukas C. Amler,Garret M. Hampton,John G. Moffat,Marcia Belvin,Mark R. Lackner	2012	155
14	Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes PLoS ONE ·Jeffrey J. Wallin,Jane Guan,Kyle A. Edgar,Wei Zhou,Ross S. Francis,Nikolay Y. Tsiberman,Peter M. Haverty,Jeffrey Eastham‐Anderson,Sabrina Arena,Alberto Bardelli,Sue Griffin,Jane Goodall,Yinhao Li,Klaus P. Hoeflich,C Torrance,Marcia Belvin,Lori S. Friedman	2012	39
15	Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes Molecular Cancer Research ·Xiaolan Hu,Howard M. Stern,Lin Ge,Carol O’Brien,Lauren E. Haydu,Gallaba Mudiyanselage Anuradha Dhananjaya,Peter M. Haverty,Brock A. Peters,Thomas D. Wu,Lukas C. Amler,John Chant,David Stokoe,Mark R. Lackner,Guy Cavet	2009	177
16	Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab Clinical Cancer Research ·Evelyn Yao,Wei Zhou,Si Tuen Lee-Hoeflich,Tom Truong,Peter M. Haverty,Jeffrey Eastham‐Anderson,Nicholas Lewin‐Koh,Bert Gunter,Marcia Belvin,Lesley Murray,Lori S. Friedman,Mark X. Sliwkowski,Klaus P. Hoeflich	2009	104
17	Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms Cancer Research ·Joshua S. Kaminker,Yan Zhang,Aleksandra Dziadykiewicz,Peter M. Haverty,Brock A. Peters,Dragan Sebisanovic,Jeremy Stinson,William F. Forrest,J. Fernando Bazán,Somasekar Seshagiri,Zemin Zhang	2007	104
18	Limited agreement among three global gene expression methods highlights the requirement for non-global validation Bioinformatics ·Peter M. Haverty,Li‐Li Hsiao,Steven R. Gullans,Ulla Hansen,Zhiping Weng	2004	17
19	CARRIE web service: automated transcriptional regulatory network inference and interactive analysis Nucleic Acids Research ·Peter M. Haverty,Martin C. Frith,Zhiping Weng	2004	28
20	CisML: an XML-based format for sequence motif detection software Bioinformatics ·Peter M. Haverty,Zhiping Weng	2004	6

About Peter M. Haverty

Peter M. Haverty is a scholar working on Cancer Research, Molecular Biology, Oncology, Geriatrics and Gerontology and Physiology, having authored 38 papers that have together received 3.3k indexed citations. Recurring topics across this work include Gene expression and cancer classification (9 papers), Cancer Genomics and Diagnostics (8 papers), Bioinformatics and Genomic Networks (7 papers), Genomics and Chromatin Dynamics (7 papers), Epigenetics and DNA Methylation (4 papers), Ubiquitin and proteasome pathways (4 papers), Cancer-related Molecular Pathways (4 papers) and Molecular Biology Techniques and Applications (3 papers). The work is most often cited by research in Cancer Research (677 citations), Molecular Biology (2.4k citations), Oncology (846 citations), Pathology and Forensic Medicine (277 citations) and Rheumatology (229 citations). Peter M. Haverty has collaborated with scholars based in United States, France and Singapore. Frequent co-authors include Zemin Zhang, Richard Bourgon, Lori S. Friedman, John Chant, Klaus P. Hoeflich, Marcia Belvin, Robert L. Yauch, David Stokoe, Karen E. Gascoigne and Steve Lianoglou. Their work appears in journals such as Clinical Cancer Research, Cancer Research, Nucleic Acids Research, PLoS ONE and Bioinformatics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact